Compare Bank of Nova Scotia (BNS) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Cytokinetics Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $107.95B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Bank of Nova Scotia is far larger — about 10× Cytokinetics Inc's market cap, and Bank of Nova Scotia pays a 3.65% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BNS | CYTK | |
|---|---|---|
Market Cap | $107.95B | $10.78B |
Sector | Financials | Technology |
52-Week High | $90.29 | $87.26 |
52-Week Low | $56.41 | $34.31 |
Dividend Yield | 3.65% | — |
Enterprise Value | — | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.85, up 0.6% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong analyst support, a 52.63% buy rating, and a solid dividend yield. Revenue grew to $37.10B in 2025, though net income margin dipped slightly to 20.99%.
Outlook is positive with earnings growth and strategic acquisitions like MapleMark Bank driving upside. Risks include economic sensitivity and competitive pressures. Wall Street sentiment leans bullish, but investors should monitor credit conditions and interest rate impacts on banking performance.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
